316 related articles for article (PubMed ID: 21735446)
21. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
22. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
24. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
Hattangadi JA; Hong TS; Yeap BY; Mamon HJ
Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088
[TBL] [Abstract][Full Text] [Related]
25. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
26. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of extracapsular lymph node involvement in pancreatic ductal adenocarcinoma.
Sergeant G; Ectors N; Fieuws S; Aerts R; Topal B
Ann Surg Oncol; 2009 Nov; 16(11):3070-9. PubMed ID: 19649555
[TBL] [Abstract][Full Text] [Related]
28. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
29. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
30. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
31. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.
Zenali M; Overman MJ; Rashid A; Broaddus RB; Wang H; Katz MH; Fleming JB; Abbruzzese JL; Wang H
Hum Pathol; 2013 Dec; 44(12):2792-8. PubMed ID: 24139211
[TBL] [Abstract][Full Text] [Related]
33. Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Kim J; Wong JY; Chen YJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S580-7. PubMed ID: 25956577
[TBL] [Abstract][Full Text] [Related]
34. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
35. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
36. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database.
Hu H; Xu Y; Zhang Q; Gao Y; Wu Z
Expert Rev Anticancer Ther; 2024 Jun; 24(6):467-476. PubMed ID: 38656796
[TBL] [Abstract][Full Text] [Related]
37. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
40. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
